Foresee Pharmaceuticals Co Ltd
Foresee Pharmaceuticals Co., Ltd. operates as biopharmaceutical company in the United States, China, and Europe. The company's stabilized injectable formulation pipeline includes FP-001, which completed Phase III clinical study for the treatment of advanced stage prostate cancer; FP-004 that is in preclinical stage to treat opioids use disorder; FP-011 and FP-014, a long-acting sustained release … Read more
Foresee Pharmaceuticals Co Ltd (6576) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2025: -0.162x
Based on the latest financial reports, Foresee Pharmaceuticals Co Ltd (6576) has a cash flow conversion efficiency ratio of -0.162x as of June 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$-157.53 Million) by net assets (NT$971.84 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Foresee Pharmaceuticals Co Ltd - Cash Flow Conversion Efficiency Trend (2017–2024)
This chart illustrates how Foresee Pharmaceuticals Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Foresee Pharmaceuticals Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Foresee Pharmaceuticals Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
NUEV.EXP.TEX.INH.EO-016
F:B02
|
N/A |
|
Foosung
KO:093370
|
0.115x |
|
Nova Minerals Limited
NASDAQ:NVA
|
-0.019x |
|
Great Taipei Gas Corp
TW:9908
|
0.056x |
|
Jiangsu Boiln Plastics Co. Ltd.
SHE:301003
|
0.029x |
|
TaiMed Biologics
TWO:4147
|
0.029x |
|
Cartesian Growth Corporation III Class A Ordinary Shares
NASDAQ:CGCT
|
-0.001x |
|
K&F Growth Acquisition Corp. II Class A Ordinary shares
NASDAQ:KFII
|
-0.002x |
Annual Cash Flow Conversion Efficiency for Foresee Pharmaceuticals Co Ltd (2017–2024)
The table below shows the annual cash flow conversion efficiency of Foresee Pharmaceuticals Co Ltd from 2017 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | NT$1.60 Billion | NT$-1.17 Billion | -0.734x | -2.93% |
| 2023-12-31 | NT$1.24 Billion | NT$-887.55 Million | -0.713x | -178.45% |
| 2022-12-31 | NT$910.58 Million | NT$-233.22 Million | -0.256x | -58.50% |
| 2021-12-31 | NT$1.32 Billion | NT$-213.33 Million | -0.162x | +56.19% |
| 2020-12-31 | NT$1.83 Billion | NT$-674.80 Million | -0.369x | +26.20% |
| 2019-12-31 | NT$895.86 Million | NT$-447.82 Million | -0.500x | +46.10% |
| 2018-12-31 | NT$498.62 Million | NT$-462.43 Million | -0.927x | -15.89% |
| 2017-12-31 | NT$603.66 Million | NT$-483.10 Million | -0.800x | -- |